A Study to Learn More About Prevenar 20 Once it is Out in the Korean Market

← catalyst calendar

NCT06760208 · readout in 194 d

Sponsored by Pfizer (industry) · PFE — their whole pipeline →.

Phase

—

Status

Recruiting

Study type

Observational

Enrollment

660estimated

Sites

Country

South Korea

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2025-11-13

actual

When the study began enrolling

Primary completion

2027-03-01

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2027-03-01

estimated

The whole study's end, after follow-up

First posted

2025-01-06

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-03-12

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

Pneumococcal Immunization
Safety

Intervention

Biological: Pneumococcal 20-valent conjugate vaccine

Primary outcomes

what the primary-completion date above is the date OF

Frequency of solicited systemic reactions

measured From Day 1 through Day 7 after vaccination, where Day 1 is the day of vaccination

Frequency of solicited local reactions

measured From Day 1 through Day 10 after vaccination, where Day 1 is the day of vaccination

Frequency of Adverse Events (AEs)